revenue growth
3–4 pct
FY 2026
official guidance
| Revenue | $1.8B |
|---|---|
| Operating income | $372.3M |
| Net income | $263.4M |
| Free cash flow | $263.0M |
| Operating margin | 20.6% |
| Net margin | 14.6% |
| Return on equity | 6.6% |
| Period | 2026 |
OpenFilings analyst
Agentic read of the latest earnings call — recommendation updates when we process a new transcript. Research synthesis, not investment advice.
Strong HST backlog and higher EPS guidance outweigh still-guarded industrial trends.
Latest call · Q1 2026Buy: IDEX delivered 5% organic sales growth, 10% organic orders growth, 26.0% adjusted EBITDA margin, and raised 2026 adjusted EPS guidance to $8.35-$8.55 from $8.15-$8.35.
HST is the clear engine—11% sales growth and 17% orders growth, supported by data center, semiconductor, space and defense demand—though the thesis still depends on acquired-business margin improvement while FMT and FSDP remain broadly flat and cyclical recovery is not yet broad-based.
HST backlog growth and continued high-single-digit to double-digit demand should support execution through the next two quarters.
Q2 guidance calls for 3%-4% organic growth, 26.5%-27.0% adjusted EBITDA margin and $2.07-$2.12 adjusted EPS.
FMT orders rose 9% organically, led by water, mining and pumps, but revenue conversion remains a key near-term watchpoint.
Short-cycle industrial activity improved from January through April, but management characterized the recovery as mixed and modeled FMT and FSDP as flattish for the year.
The company plans to repurchase approximately $76 million of stock per quarter through 2026; tariffs are currently expected to have little net financial impact.
HST has a credible multiyear runway in data-center power and thermal management, semiconductor consumables and equipment, optical switching, and space and defense.
IDEX's component orientation and early customer co-engineering may create switching costs and allow technologies to be redeployed across advantaged applications.
The 8020 operating model is being extended across integrated growth platforms, with capital and talent shifting toward higher-value markets and customers.
Bolt-on M&A remains active and can broaden the Materials Science Solutions and HST platforms while preserving the buyback program.
Water is a structural growth area through municipal storm-water infrastructure and high-purity water demand tied to semiconductor manufacturing.
HST incremental EBITDA flow-through was only about 33% and is expected to reach merely the mid-30% range in 2026; management does not expect approximately 40% flow-through until potentially 2027.
Recently acquired businesses including Muon, Micro-LAM and Mott remain below HST's roughly 26%-27% segment EBITDA margin, making portfolio pruning and integration execution critical.
Life sciences remains pressured by China exposure, constrained NIH funding and academic spending; its recovery is an assumption behind longer-term HST margin expansion rather than an established trend.
Management explicitly said the guidance increase is driven more by internal growth initiatives and M&A than by a genuine cyclical industrial rebound.
FMT orders have outpaced sales for several quarters, and management retained a flattish full-year FMT outlook despite Q1 orders growth, limiting confidence in backlog conversion.
HST backlog visibility is better than IDEX's historical norm but is primarily within 12 months; longer-dated growth claims rely on customer discussions rather than firm disclosed commitments.
revenue growth
3–4 pct
FY 2026
official guidance
ebitda
26.5–27 pct
FY 2026
official guidance
adjusted eps
8.35–8.55 $per share
FY 2026
official guidance
revenue growth
3–4 pct
Q2 2026
official guidance
ebitda
26.5–27 pct
Q2 2026
official guidance
adjusted eps
2.07–2.12 $per share
Q2 2026
official guidance
OpenFilings analyst view from primary-source filings and earnings calls — not investment advice.
IDEX CORPORATION
IDEX CORPORATION
IDEX CORPORATION
IDEX CORPORATION
IDEX CORPORATION
IDEX CORPORATION